S-EPMC4963009 - Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. - OmicsDI

Unknown

Dataset Information

Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia.

ABSTRACT:

SUBMITTER: Patel V

PROVIDER: S-EPMC4963009 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature